mRNA expression of chemosensitivity genes as a predictor of response to neoadjuvant chemotherapy in non-small cell lung cancer
| Autor: | M. M. Tsyganov, I. V. Deryusheva, E. O. Rodionov, L. A. Efteev, S. V. Miller, M. K. Ibragimova, E. E. Perminova, O. V. Cheremisina, I. G. Frolova, S. A. Tuzikov, N. V. Litviakov |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty response to chemotherapy medicine.medical_treatment 030204 cardiovascular system & hematology 03 medical and health sciences GSTP1 0302 clinical medicine Internal medicine Gene expression medicine Gene non-small cell lung cancer RC254-282 TUBB3 Chemotherapy business.industry chemosensitivity genes Neoplasms. Tumors. Oncology. Including cancer and carcinogens Reverse transcriptase Real-time polymerase chain reaction 030220 oncology & carcinogenesis gene expression ERCC1 business neoadjuvant chemotherapy |
| Zdroj: | Sibirskij Onkologičeskij Žurnal, Vol 18, Iss 1, Pp 13-20 (2019) |
| ISSN: | 2312-3168 1814-4861 |
| Popis: | The objective response rate to neoadjuvant chemotherapy (NAC) in patients with non-small cell lung cancer (NSCLC) is approximately 16 %. Therefore, the search for new predictive factors and markers that could precisely predict the NAC response and be relevant to the choice of the adequate treatment policy is of utmost importance. the purpose of the study was to analyze the relationship between the expression levels of chemosensitivity genes and NAC response in patients with non-small cell lung cancer. material and methods. The study included 30 patients with stage IIAIIIB NSCLC. Total RNA was isolated from normal and tumor lung tissue samples prior to NAC. The expression level of chemosensitivity genes, such as BRCA1, RRM1, ERCC1, TOP1, TOP2a, TUBB3, TYMS, and GSTP1 was evaluated by real-time reverse transcriptase quantitative PCR (RT-qPCR). results. A significant difference in the expression levels of the studied genes between patients with different NAC response was found. The objective response to therapy was observed in 67 % (10/15) of patients having no ERCC1 expression compared to those with ERCC1 expression (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|